Supprelin La

(histrelin acetate)

Phase 3Small molecule

UUniversity of New Hampshire

Supprelin La is one of 48 small molecule programs targeting Metastatic Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Metastatic Prostate CancerRecruiting

Metastatic Prostate CancerPhase 3

Recruiting

Competition

Competitive Landscape

75 competitors in Metastatic Prostate Cancer

#DrugCompanyPhaseTrials

Zytiga

Johnson & Johnson

Phase 3

21 2

Xtandi

Astellas

Phase 3

18 3

Taxotere

AAvyxa

Phase 3

42 4

Erleada

Johnson & Johnson

Phase 3

14 5

Nubeqa

Bayer

Phase 3

7 6

Rayos

RRoxane Laboratories

Phase 3

19 7

Jevtana

Sanofi

Phase 3

5 8

Lupron

EEastern Cooperative Oncology Group

Phase 3

9 9

Zoladex

TTerSera Therapeutics LLC

Phase 3

7 10

Paraplatin

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 3Recruiting

Metastatic Prostate Cancer

NCT03678025

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer

Completed· Endo Pharmaceuticals logo

Endo Pharmaceuticals·Phase 3·NCT01697384·138 enrolled

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

Completed·UUniversity of Colorado, Denver·Phase 2·NCT02278185·19 enrolled

Metastatic Prostate Cancer1 trial

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Recruiting·SSWOG Cancer Research Network·Phase 3·NCT03678025·1,273 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 24, 1991

SUPPRELIN

NDA NDA019836

Oct 12, 2004

VANTAS

NDA NDA021732

May 3, 2007

SUPPRELIN LA

NDA NDA022058

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for histrelin acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — histrelin acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for histrelin acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA022058). U.S. Food & Drug Administration.
[5]
SEC EDGAR — University of New Hampshire company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of New Hampshire

Supprelin La

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Prostate Cancer2 trials

Metastatic Prostate Cancer1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News